Investigating the effect of budesonide nebulizer on healing and treatment process of children with pneumonia aged 1 month to 5 years: a randomized clinical trial

Document Type : Research Paper

Authors

1 Pediatric Resident, Department of pediatrics, school of medicine, Shahrekord University of Medical Sciences, Shahrekord, Iran

2 Modeling in Health Research Center, Shahrekord University of Medical Sciences, Shahrekord, Iran

3 Assistant professor of Allergy and clinical Immunology, Department of pediatrics, school of medicine, Shahrekord University of Medical Sciences, Shahrekord, Iran

Abstract

Background: Pneumonia is the first cause of death in children worldwide. Using anti-inflammatory drugs such as corticosteroid with antimicrobial treatment can be a suitable treatment.
Objectives: This study was conducted to investigate the effect of budesonide nebulizer on the healing process and treatment of children with pneumonia aged 1 month to 5 years.
Methods: This study is a randomized clinical trial, conducted in 2024 in Hajar Shahrekord Hospital on 122 children With Community Acquired Pneumonia aged 1 month to 5 years. After Initial examinations, serum WBC, ESR and CRP levels and PRESS score were measured before the intervention. Children were randomly divided into intervention (n=61) and control (n=61) groups. In addition to the usual treatments, the intervention group was given 0.5 mg budesonide nebulizer every 12 hours for 5 days. During the study, body temperature, heart rate and respiratory rate, blood oxygen saturation, pulmonary Rale, cough frequency and days of hospitalization were recorded. At the end of the intervention, serum factors were measured again.
Results: The results showed there was no significant difference in hospitalization days, body temperature, respiratory rate and heart rate, blood oxygen saturation, cough frequency, pulmonary rales and accessory muscles use (0.05˂p). WBC, ESR and CRP changes before and after intervention between the 2 groups hadn’t significant differences (p=0.77)
Conclusions: Budesonide nebulizer didn’t have a significant effect on hospitalization days, heart rate, respiratory rate, O2 saturation, cough frequency, accessory muscles use, pulmonary rales and fever disappearance and inflammatory markers during the study.

Keywords

Main Subjects

References

  1. Shoar S, Musher DM. Etiology of community-acquired pneumonia in adults: a systematic review. Pneumonia. 2020;12:1-10.
  2. Amini S, Omidi AH, Afkhami H, Sabati H, Mohsenzadeh A, Soleymani A, et al. Frequency of aac (6 ́)-le-aph (2 ́ ́) gene and resistance to Aminoglycoside antibiotics in Staphylococcus aureus isolates. Cell Mol Biomed Rep. 2024;4(2):120-8.
  3. Soltan Dallal MM, Rajabi Z, Papizadeh M, Amiri S, Foroushani AR, Naser A, et al. Prevalence of extended-spectrum β-lactamase (ESBL)-producing Escherichia coli associated with outbreaks of food-borne gastroenteritis in Tehran. Cell Mol Biomed Rep. 2024;4(4):199-207.
  4. Adaji EE, Ekezie W, Clifford M, Phalkey R. Understanding the effect of indoor air pollution on pneumonia in children under 5 in low-and middle-income countries: a systematic review of evidence. Environmental Science and Pollution Research. 2019;26:3208-25.
  5. Bolursaz MR, Lotfian F, Ghaffaripour HA, Hassanzad M. Underlying causes of persistent and recurrent pneumonia in children at a pulmonary referral hospital in Tehran, Iran. Archives of Iranian medicine. 2017;20(5):266-9.
  6. Gu X, Pan L, Liang H, Yang R, editors. Classification of bacterial and viral childhood pneumonia using deep learning in chest radiography. Proceedings of the 3rd international conference on multimedia and image processing; 2018.
  7. de Benedictis FM, Kerem E, Chang AB, Colin AA, Zar HJ, Bush A. Complicated pneumonia in children. The Lancet. 2020;396(10253):786-98.
  8. Helgeson SA, Levitt JE, Festic E. Systemic and inhaled corticosteroids, with or without beta agonists, as adjuvant therapy in community acquired pneumonia. 2020.
  9. Matera MG, Rogliani P, Ora J, Cazzola M. Current pharmacotherapeutic options for pediatric lower respiratory tract infections with a focus on antimicrobial agents. Expert opinion on pharmacotherapy. 2018;19(18):2043-53.
  10. Esposito S, Bianchini S, Argentiero A, Neglia C, Principi N. How does one choose the appropriate pharmacotherapy for children with lower respiratory tract infections? Expert Opinion on Pharmacotherapy. 2020;21(14):1739-47.
  11. Bradley JS, Byington CL, Shah SS, Alverson B, Carter ER, Harrison C, et al. The management of community-acquired pneumonia in infants and children older than 3 months of age: clinical practice guidelines by the Pediatric Infectious Diseases Society and the Infectious Diseases Society of America. Clinical infectious diseases. 2011;53(7):e25-e76.
  12. Stern A, Skalsky K, Avni T, Carrara E, Leibovici L, Paul M. Corticosteroids for pneumonia. Cochrane Database of Systematic Reviews. 2017(12).
  13. Briel M, Spoorenberg SM, Snijders D, Torres A, Fernandez-Serrano S, Meduri GU, et al. Corticosteroids in patients hospitalized with community-acquired pneumonia: systematic review and individual patient data metaanalysis. Clinical Infectious Diseases. 2018;66(3):346-54.
  14. Meijvis SC, Hardeman H, Remmelts HH, Heijligenberg R, Rijkers GT, van Velzen-Blad H, et al. Dexamethasone and length of hospital stay in patients with community-acquired pneumonia: a randomised, double-blind, placebo-controlled trial. The Lancet. 2011;377(9782):2023-30.
  15. Chalmers JD. Corticosteroids for community-acquired pneumonia: a critical view of the evidence. Eur Respiratory Soc; 2016. p. 984-6.
  16. Price D, Castro M, Bourdin A, Fucile S, Altman P. Short-course systemic corticosteroids in asthma: striking the balance between efficacy and safety. European Respiratory Review. 2020;29(155).
  17. Jahn‐Bassler K, Bauer WM, Karlhofer F, Vossen MG, Stingl G. Sequential high‐and low‐dose systemic corticosteroid therapy for severe childhood alopecia areata. JDDG: Journal der Deutschen Dermatologischen Gesellschaft. 2017;15(1):42-7.
  18. LI G. Clinical curative effect of budesonide inhalation in the treatment of children with Pneumonia. Chinese Journal of Primary Medicine and Pharmacy. 2015:181-3.
  19. Duan Y, Zhou H, Chen J. The effects of the atomization inhalation of budesonide, salbutamol, and ipratropium bromide on the T-lymphocyte subset and inflammatory cytokine levels in children with asthmatic pneumonia. American journal of translational research. 2021;13(9):10517.
  20. Kukhon FR, Festic E. Adjuvant inhaled corticosteroids in community-acquired pneumonia: a review article. Medical Sciences. 2021;9(2):34.
  21. Li B, Han S, Liu F, Kang L, Xv C. Budesonide nebulization in the treatment of neonatal ventilator associated pneumonia. Pakistan journal of medical sciences. 2017;33(4):997.
  22. Thokngaen J, Karoonboonyanan W. Pediatric respiratory severity score evaluates disease severity of respiratory tract infection in children. Chulalongkorn Medical Journal. 2019;63(1):41-6.
  23. Yallew WW, Assefa S, Yemane B. Pneumonia among under–five children in Ethiopia: a retrospective analysis from an urban hospital. Research Square. 2023.
  24. Li Y, An Z, Yin D, Liu Y, Huang Z, Ma Y, et al. Disease burden of community acquired pneumonia among children under 5 y old in China: A population based survey. Human vaccines & immunotherapeutics. 2017;13(7):1681-7.
  25. Cinar N, Dede C, Cevahir R, Sevimli D. Smoking status in parents of children hospitalized with a diagnosis of respiratory system disorders. Bosnian Journal of Basic Medical Sciences. 2010;10(4):319.
  26. Minawati AD, Murti B, Prasetya H. Meta-Analysis: Effects of Exposure to Tobacco Smoke and Malnutrition on the Risk of Pneumonia in Children. Journal of Epidemiology and Public Health. 2023;8(4):457-68.
  27. Wang C, Zhang X, Qian W, Liu X, Zhang W. Budesonide combined with ipratropium bromide in the treatment of bronchopneumonia and its efficacy on pulmonary function. INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL MEDICINE. 2020;13(2):1092-7.
  28. Gao X, Guo X, Cui K. Combined aerosol inhalation of salbutamol and budesonide effectively improves neonatal bacterial pneumonia and reduces serum inflammatory factors in newborns [J]. Chemicals & Chemistry. 2019;12(9):11684-91.
  29. Ke J, Tu X. Efficacy of Pulmicort Respules Combined with Azithromycin in the Treatment of Children with Recurrent Respiratory Tract Infection Caused by Mycoplasmal Pneumonia. British Journal of Hospital Medicine. 2024;85(11):1-11.
Medical Journal of Mashhad university of Medical Sciences
Volume 69, Issue 2
May 2026
Pages 130-141

Files

Share

How to cite

Statistics